<DOC>
	<DOCNO>NCT03061734</DOCNO>
	<brief_summary>The product investigation investigational combination two marketed product low dose . Utilizing previously unrecognized property component , component combination inhibits two distinct target newly discover molecular pathway result reduction neuro-inflammation induce pain . The investigator propose migraine cause innate immune system-induced neuro-inflammation near trigeminal nerve system . The use combination product hold strong biological rationale , act synergistically , two component contribute block two distinct neuro-inflammation produce target . The goal study establish investigational product address headache pain also migraine associate symptom , especially , nausea . Nausea associate acute Migraine represent significant unmet treatment need . Significant efficacy headache pain nausea may suggest product 's mechanism action address fundamental pathogenesis migraine .</brief_summary>
	<brief_title>ALLOD-2 ALLOD-2H v . Placebo v . Components Acute Treatment Migraine ( ANODYNE-1 )</brief_title>
	<detailed_description>The study consist screen visit , home treatment single migraine attack single dose study drug , study eligibility confirm , End-of-Study Visit 2-4 day treatment migraine attack . Patients 8-week treat Qualified Migraine attack . The duration patient ' participation study 10 week .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>1 . The patient male female 18 year age old . 2 . The patient history migraine without aura accord International Classification Headache Disorders ( ICHD ) 3rd edition ( beta version ) least oneyear . 3 . The patient 2 8 migraine per month previous 3 month . 4 . The patient first migraine prior age 50 year . 5 . The patient agrees take medication treat acute migraine within 24 hour take study drug . 6 . The patient agree refrain take opiate medication randomization 7 day take study drug . 7 . The patient agree refrain take medication treat migraine 2 hour take study drug . 8 . The patient able complete study questionnaire , comply study requirement restriction , willing provide write informed consent authorize HIPAA . 9 . The female patient premenopausal postmenopausal le 1 year , surgical sterilization ( i.e. , tubal ligation , partial complete hysterectomy ) must negative urine pregnancy test , nonlactating , commit use adequate reliable contraception throughout study ( e.g. , barrier additional spermicidal , intrauterine device , hormonal contraception ) . The male patient must surgically sterile commit use 2 different method birth control study 28 day take study drug . 1 . The patient may vomit migraine attack . 2 . The patient opinion investigator , may medicationoveruse headache pain ( analgesicoveruse , opioidoveruse , ergotamineoveruse , triptanoveruse ) . 3 . The patient 10 headache day per month due chronic migraine headache disorder past 12 month . Alternatively , patient consume medication treat headache 10 day per month past 12 month . 4 . The patient history cluster headache neurologically complicate migraine ( hemiplegic , basilar , retinal , ophthalmoplegic migraine ) . 5 . The patient us opiates barbiturate 3 dos per month . 6 . The patient treat botulinum toxin treatment head neck area within 3 month inclusion trial . 7 . The patient currently use blood thin medication regular basis ( i.e. , warfarin heparin ) . 8 . The patient initiate changed medication possible migraine prophylactic effect 3 month inclusion trial ( E.g. , calcium channel blocker , tricyclic antidepressant , betablockers , selective serotonin reuptake inhibitor ( SSRIs ) serotoninnorepinephrine reuptake inhibitor ( SNRIs ) ) . 9 . The patient concurrent medical psychiatric condition , include , limited chronic unstable debilitating diseases parkinson 's disease , multiple sclerosis , cancer , significant renal impairment , significant hepatic impairment , heart disease , etc . 10 . The patient history within previous 3 year abuse drug , prescription , illicit , alcohol . 11 . The Female patient pregnant breastfeeding . 12 . The Male patient practice 2 different method birth control partner study , 28 day investigational drug last dose remain abstinent study , 28 day last dose . 13 . The patient knownhypersensitivity reaction component investigational drug . 14 . The patient participate another study investigational drug within 30 day prior randomization and/or plan participate study . 15 . The patient consume analgesic medication condition regular basis , ( nonsteroidal antiinflammatory drug , acetaminophen muscle relaxant , ( Cyclobenzaprine , carisoprodol , etc. ) . 16 . The patient use emergency care treatment 3 time previous 6 month . 17 . The patient opinion investigator , unsuitable participate study reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Migraine Disorders</keyword>
	<keyword>Headache Disorders</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
</DOC>